Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Application value of multi-target stool FIT-DNA test (ColoClear) in patients with early colorectal cancer and precancerous lesions and their first-degree relatives: a prospective study

ABSTRACT: Interventions: Gold Standard:Colonoscopy.;Index test:Multi-target stool FIT-DNA test (ColoClear). Primary outcome(s): Sensitivity;Specificity;Positive predictive value;Negative predictive value Study Design: Cohort study

DISEASE(S): Colorectal Cancer

PROVIDER: 2725412 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A prospective study on the application of Multi-target Stool FIT-DNA Test (ColoClear) in colorectal cancer screening and the practical verification of genetic and lifestyle factors

Project description:Interventions: Gold Standard:colonoscopy;Index test:Multi-target Stool FIT-DNA Test (ColoClear) ; Fecal immunochemical test(Pupu Tube) Primary outcome(s): Sensitivity;Specificity;Positive predictive value;Negative predictive value;Coincidence Rate;Morbidity Study Design: Cohort study

| 2662204 | ecrin-mdr-crc

Artificial intelligence assisted endocytoscopy in real-time diagnosis of early colorectal cancer

Project description:Interventions: Gold Standard:Pathological test;Index test:1. Endoscopy; 2. Artificial intelligence real-time diagnosis system. Primary outcome(s): Diagnostic accuracy;Sensitivity;Specificity;Positive predictive value;Negative predictive value Study Design: Sequential

| 2725610 | ecrin-mdr-crc

Performance of new biomarkers and technologies for colorectal cancer screening

Project description:Interventions: Gold Standard: Taking colonoscopy together with pathological examination results as the gold standard.;Index test:Detection of miR-92a in stool samples; Detection of Septin9 in plasma samples; Detection of FIT-DNA in stool samples; Fecal immunochemical test. Primary outcome(s): Sensitivity;Specificity;Positive predictive value;Negative predictive value Study Design: Diagnostic test for accuracy

| 2662086 | ecrin-mdr-crc

Molecular Diagnostic Program for Early Screening of Colorectal Cancer in China

Project description:Interventions: Gold Standard:Pathological diagnosis;Index test:Early screening model of colorectal cancer Primary outcome(s): Sensibility;Specificity;Positive Predictive Value;Negative Predictive Value;Tissue Biomarker Methylation;Tissue Biomarker Mutation;Blood Biomarker Methylation;Stool Mutation;Stool Methylation;Stool Bacteria Study Design: Sequential

| 2688309 | ecrin-mdr-crc

Clinical study of fecal SDC2 / TFPI2 methylation combined with FIT in the detection of colorectal cancer and precancerous lesions

Project description:Interventions: Gold Standard:colonoscopy/pathological diagnosis;Index test:fecal SDC2 / TFPI2 methylation combined with FIT Primary outcome(s): fecal SDC2 / TFPI2 methylation;stool occult blood test;colonoscopic results;pathologic results Study Design: Factorial

| 2725740 | ecrin-mdr-crc

Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects.

Project description:BACKGROUND:Genetic analyses have identified many variants associated with the risk of inflammatory bowel disease (IBD) development. Among these variants, the ones located within the NOD2 gene have the highest odds ratio of all IBD genetic risk variants. Also, patients with Crohn's disease (CD) have been shown to have an altered gut microbiome, which might be a reflection of inflammation itself or an effect of other parameters that contribute to the risk of the disease. Since NOD2 is an intracellular pattern recognition receptor that senses bacterial peptidoglycan in the cytosol and stimulates the host immune response (Al Nabhani et al., PLoS Pathog 13:e1006177, 2017), it is hypothesized that NOD2 variants represent perfect candidates for influencing host-microbiome interactions. We hypothesized that NOD2 risk variants affect the microbiome composition of healthy first degree relative (FDR) of CD patients and thus potentially contribute to an altered microbiome state before disease onset. METHODS:Based on this, we studied a large cohort of 1546 healthy FDR of CD patients and performed a focused analysis of the association of three major CD SNPs in the coding region of the NOD2 gene, which are known to confer a 15-40-fold increased risk of developing CD in homozygous or compound heterozygous individuals. RESULTS:Our results show that carriers of the C allele at rs2066845 was significantly associated with an increase in relative abundance in the fecal bacterial family Erysipelotrichaceae. CONCLUSIONS:This result suggests that NOD2 polymorphisms contribute to fecal microbiome composition in asymptomatic individuals. Whether this modulation of the microbiome influences the future development of CD remains to be assessed.

| S-EPMC7566148 | biostudies-literature

First-degree relatives of cancer patients: a target group for primary prevention? A cross-sectional study.

Project description:BACKGROUND:Persons with a first-degree relative (FDR) with cancer are at increased cancer risk. We investigated preventive behaviour, cancer risk perception and readiness to change an unhealthy lifestyle in persons with and without an FDR with cancer. METHODS:Using an online questionnaire, we conducted a cross-sectional study in Germany including persons (≥35 years) with an FDR with colorectal, lung, prostate, breast, stomach or cervical/uterine cancer (n = 621) and persons without cancer in FDRs (n = 303). Quota sampling ensured similar age and sex distributions in both groups. RESULTS:Unfavourable lifestyle factors were equally common in both groups. The proportion perceiving an increased cancer risk significantly differed (p < 0.0001) with 4% among respondents without cancer in FDRs and 18% (colorectal cancer) to 30% (stomach cancer) among cancer patients' relatives. The proportion of smokers ready to quit smoking was significantly higher among those perceiving an increased vs. a lower cancer risk (64 vs. 46%, p = 0.04). There was a similar association for readiness to increase physical activity and consumption of fruits/vegetables and to reduce alcohol consumption. CONCLUSIONS:Given the increased risk perception and motivation to change an unhealthy lifestyle, our study provides a strong rationale for research on the effectiveness of lifestyle interventions in cancer patients' relatives.

| S-EPMC5943415 | biostudies-literature

Stool DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer

Project description:Interventions: Gold Standard:colonoscopy;Index test:Stool DNA methylation biomarkers. Primary outcome(s): accuracy Study Design: Diagnostic test for accuracy

| 2680588 | ecrin-mdr-crc

Stool DNA Testing for opportunistic screening of High-risk Colorectal Cancer population

Project description:Interventions: Gold Standard:Histopathological diagnosis of colorectal cancer to be the gold standard;Index test:1. Human sdc2 gene methylation detection kit; 2. Fecal Immunochemical Test. Primary outcome(s): Stool DNA Testing;colonoscopy;SPE, SEN, ACC, AUC of ROC Study Design: Sequential

| 2682966 | ecrin-mdr-crc

Validity and diagnostic performance of an optimized multi-target stool nucleic acid test combined with FIT (ColoAlert 3.0) for early detection of colorectal cancer and advanced precancerous lesions in colon

Project description:Interventions: Group 1: Participants who either have a screening colonoscopy, are referred for diagnostic colonoscopy, or have been diagnosed with a colorectal lesion (therapy-naive) that could be part of this study are eligible for participation in this study. They will be invited to participate in the study when they are referred for colonoscopy (pre-inclusion). After being informed and signing an informed consent form, the subjects will give a stool sample at least two days before the colonoscopy and before the colonic irrigation. The stool sample will be analysed using ColoAlert 3.0. After the colonoscopy, they are assigned to one of the three macroscopically defined groups (CRC, APL or normal colon). However, if the PAD from a biopsy taken under routine conditions does not match the macroscopically defined diagnosis, they are excluded from the evaluation. Subjects who do not belong to one of the 3 groups will also be excluded from the evaluation. Primary outcome(s): • To determine sensitivity for CRC with the ColoAlert 3.0 test • To determine specificity for CRC with the ColoAlert 3.0 test Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other

| 2727277 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data